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(DAS28)Abstract Aim of the work: Monocytes are divided into three major subsets based on the expres-
sion of the cluster of differentiation CD14 and CD16. The aim of this work was to determine which
of the CD16+ monocyte subpopulations is expanded in rheumatoid arthritis (RA) and its associa-
tion with disease activity and interleukin-17 (IL17) levels.
Patients and methods: Fifty-three RA patients and 20 controls were enrolled in this study. Flow
cytometry was performed to detect monocyte subsets and IL17 was measured by ELISA. Disease
activity score (DAS28) was assessed.
Results: CD14++CD16+ monocyte percentage was significantly higher in long standing RA
patients compared with early patients and controls (p< 0.01, p< 0.001 respectively). It was signif-
icantly higher in patients with RA disease activity and remission compared with the controls
(p< 0.001, p< 0.01 respectively). It was not significantly associated with resistance to disease
modifying antirheumatic drugs (DMARDs), C-reactive protein, rheumatoid factor and anti-CCP
positivity (p> 0.05). It significantly correlated with IL17 (p< 0.002). CD14+CD16+ monocyte
percentage was not significantly correlated with any of the above parameters. IL17 level was signifi-
cantly higher in patients with early and long standing RA compared to controls (p< 0.01,
p< 0.001 respectively). IL17 was higher in RA patients with active disease compared to those in
remission and controls (p< 0.01, p< 0.001 respectively). It was higher in RA patients resistant
to DMARDs than in responding patients (p< 0.017).
Conclusion: CD14++CD16+ monocyte subpopulation was expanded in long standing RA and
was correlated with IL17 levels indicating its potential pathogenic importance in RA and may rep-
resent an attractive target for future therapeutic interventions.
 2015 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Alkom,
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Accumulating evidence supports that cluster of differentiation
CD4+CD25+ regulatory T cells play an essential role in con-
trolling rheumatoid arthritis (RA) [1]. T helper-17 cells and
interleukin (IL-17) play an important role in the pathogenesis
of inflammatory and destructive pattern characteristic [2]. In a
previous study, proteinase-activated receptor-2 expression on
monocytes was remarkably high in active RA patients and
consistent with a pathogenic role while its expression on
CD3+ T-cells was not [3].
Cells of the monocyte/macrophage lineage play important
roles in RA pathogenesis, the perpetuation of inflammation,
and are potential targets for activation by immune complexes
(ICs). Activated macrophages are the predominant infiltrating
cells found in RA synovium, pannus and nodules [4,5]. Macro-
phages play a role in phagocytosis, antigen presentation,
antibody-dependant cell-mediated cytotoxicity and release of
pro-inflammatory cytokines and tissue destructive mediators
[6]. The migration of monocytes from blood to synovial tissue
and their differentiation into macrophages may be an impor-
tant step in disease pathogenesis [7]. Macrophages are the
major source of pro-inflammatory cytokines in the inflamed
RA joint including tumor necrosis factor (TNF), interleukin-
1 (IL-1), IL-8 and granulocyte–macrophage colony-
stimulating factor (GM-CSF) [4,8]. FccRIIIa cross-linking
has been specifically implicated in cytokine release from adher-
ent human monocytes/macrophages [9,10]. These cytokines are
intimately involved in the disease process as demonstrated by
the clinical efficacy of TNF or IL-1 blockade in RA [11,12].
Current knowledge defines three major monocyte subsets
based on the expression patterns of CD16 and the receptor
CD14: classical CD14++CD16, intermediate CD14++
CD16+ and non-classical CD14+CD16+ monocytes [13].
These subsets differ essentially in their chemokine receptor
expression, phagocytic activity and tissue distribution during
inflammation or steady-state conditions [14]. Hence, monocyte
subsets are differentially involved in the pathophysiology of
inflammation, atherosclerosis and regeneration after injuryTable 1 Demographic and laboratory features in the rheumatoid a
activity in RA patients.
Characteristics
mean ± SD (range) or n (%)
RA patients (n= 53)
Early Late
(n= 19) (n= 34
Age (years) 42.6 ± 11.3 45.1 ±
(22–61) (22–64)
Disease duration (yr) 1.4 ± 0.68 10.2 ±
Sex
Male 4 (21.1) 3 (8.8)
Female 15 (78.9) 31 (91.2
Disease activity 15 (78.9) 24 (70.6
Disease remission 4 (21.1) 10 (29.4
CRP positivity 13 (68.4) 22 (64.7
RF positivity 15 (78.9) 30 (88.2
Anti-CCP positivity 14 (73.7) 17 (50.0
RA: rheumatoid arthritis, Early: disease duration62 years, long standing:
factor, anti-CCP: anti-cyclic citrullinated peptide.
F:ANOVA test v2:Chi square test.
* Significantly different at p< 0.05.[15–17]. In particular, the unique features of the intermediate
in contrast to the nonclassical subset (both previously referred
as CD16+ monocytes) has become recently more evident and
especially in cardiovascular disease this subset was shown to
predict independently cardiovascular events at follow-up
[18–20]. Thus, human monocyte subsets may represent a
novel prognostic marker or therapeutic targets in clinical
medicine.
The aim of the current study was to determine which of the
two CD16+ monocyte subpopulations is expanded in RA and
to investigate their possible association with disease activity
and with IL17 levels.
2. Patients and methods
The present study was conducted on 53 RA patients attending
out-patient clinic of Physical Medicine and Rehabilitation
Department, Menoufia University Hospitals and 20 age and
sex matched healthy controls. Patients were diagnosed as RA
according to ACR/EULAR classification criteria 2010 [21].
Patients were classified according to RA disease duration into
early (62 years, n= 19) and long standing RA (>2 years,
n= 34). Each group was further subdivided according to the
disease activity score in 28 joints (DAS28) [22] into 2 sub-
groups; activity and remission groups (early RA, activity
n= 15, remission n= 4; long standing RA, activity n= 24,
remission n= 10). The disease activity was further categorized
as low, moderate and high [22]. This study was approved by
the ethics committee of the Faculty of Medicine, Menoufia
University. All patients provided signed informed consent to
provide a blood sample and to review the medical record for
research purposes.
2.1. Immunophenotyping of peripheral blood monocytes
100 ll peripheral blood mononuclear cells were incubated with
20 ll FITC-conjugated antihuman CD14 and 20 ll
PE-conjugated antihuman CD16 (Immunostep, Spain) for
30 min at 4 C followed by red blood cells lysis and washingrthritis (RA) patients and controls and the disease duration and
Control Significance test
Test p
) (n= 20)
11.4 48.7 ± 7.3 F= 1.7 0.19
(30–60)
7.6 –
1 (5) v2 = 2.9 0.24
) 19 (95)
) – v2 = 0.4 0.51
)
) 0 (0) v2 = 25.4 <0.001*
) 0 (0) v2 = 44.7 <0.001*
) 0 (0) v2 = 23.1 <0.001*
disease duration >2 years, CRP: C-reactive protein, RF: rheumatoid
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ysis were done using BD FACSCalibur flow cytometry (BD
Biosciences, Franklin Lakes, New Jersey, USA). We gated
on monocytes and then analyzed the percentage of CD14++
CD16+ monocytes and CD14+CD16+ monocytes. The inten-
sity of expression of CD16 on each monocyte subset was mea-
sured as mean fluorescent intensity ratio (MFIR). Controls
and patient samples were examined using the same settings
and conditions for comparison.
2.2. Measurement of serum IL 17 level by ELISA
(eBioscience, Inc., San Diego, CA 92121, USA) It was done
according to the manufacturer’s instructions.
2.3. Statistical analysis
Analysis was performed with SPSS version 20 statistical soft-
ware. Quantitative data were expressed as mean ± standard
deviation. Two groups of non-normally distributed variables
were tested by Mann–Whitney test. Comparisons of three
groups of normally distributed variables by ANOVA test
and non-normally distributed variables by Kruskal–Wallis test
were made. Post hoc test was used after ANOVA (F test) or
Kruskal–Wallis test to show any significant difference between
the individual groups. Qualitative data were expressed as num-
ber and percentage (n and %) and analyzed by Chi-square test.
Pearson correlation was used for normally distributed while
Spearman correlation was used for non-normally distributed
quantitative variables. p value < 0.05 was considered statisti-
cally significant.Table 2 Comparison between early and long standing RA patients,
controls and different degrees of disease activity regarding IL17
CD14+CD16+ monocytes.
Parameter
mean ± SD
Rheumatoid arthritis patients (n= 53) and c
CD14++CD16+
% MFIR
Patients
Early (19) 12.01 ± 3.2#,@ 118.1 ± 41.6
Late (34) 17.03 ± 6.1# 101.5 ± 35.7
Controls 8.2 ± 2.4 107.4 ± 33.9
p <0.001 0.52
Patients
Active (39) 15.3 ± 6.01# 112.9 ± 36.7
In remission (14) 14.9 ± 5.2# 92.2 ± 30.6
Controls 8.2 ± 2.4 107.4 ± 33.9
p <0.001 0.26
Disease activity
Low (4) 15.4 ± 6.9 104.7 ± 50.3
Moderate (27) 13.8 ± 4.8* 114.6 ± 37.8
High (8) 20.6 ± 7.01 111.3 ± 45.9
p 0.038 0.92
RA: rheumatoid arthritis, MFIR: mean fluorescent intensity ratio, IL17:
The CD14++CD16+ and CD14+CD16+ were assessed in only 12 of th
# On post-hoc test; significantly different from corresponding control, a
@ On post-hoc test; significantly different from long standing patients, a
 On post-hoc test; significantly different from patients in remission, at
* On post-hoc test; significantly different from high disease activity at p3. Results
Fifty-three RA patients with a mean age of 44 ± 11.2 years
and 20 age and sex matched healthy controls were included
in this analysis. The mean disease duration was 7 ± 7.4 years.
The demographic and laboratory data of the patients and con-
trol and disease duration and activity of the patients are shown
in Table 1. The CD14++CD16+ and CD14+CD16+ mono-
cytes were assessed in only 12 of the controls while IL17 level
was measured in all the controls.
3.1. Regarding disease duration
The percentage of CD14++CD16+ monocytes was signifi-
cantly higher in long standing compared with early RA
patients and controls (p< 0.01, p< 0.001 respectively)
(Table 2, Fig. 1). It was also significantly higher in patients
with early RA compared to healthy controls (p< 0.01). The
percentage of CD14+ CD16+ monocytes were significantly
lower in early RA than healthy controls (p= 0.04). Regarding
CD16+MFIR on CD14++ and CD14+ monocytes: there was
no significant difference when comparing between the three
groups; long standing RA, early RA and controls (Table 2).
IL17 levels were significantly higher in early and long standing
RA compared to controls (p< 0.01, p< 0.001 respectively)
(Table 2).
3.2. Regarding disease activity
The percentage of CD14++CD16+ monocytes was signifi-
cantly higher in patients with RA disease activity andRA patients with active disease and those with remission, healthy
levels, the percentages and MFIR of CD14++CD16+ and
ontrol (n= 20) IL17
(pg/ml)
CD14+CD16+
% MFIR
7.9 ± 3.4# 213.9 ± 110.7 51 ± 37.3#
9.6 ± 5.1 202.8 ± 151.3 64.9 ± 43.3#
11.8 ± 3.5 194.7 ± 91.8 18.3 ± 8.1
0.04 0.52 <0.001
9.46 ± 4.3 206.6 ± 160.8 68.5 ± 42.7 ,#
7.62 ± 5.3# 207.2 ± 125.3 40.1 ± 31.4
11.8 ± 3.5 194.7 ± 91.8 18.3 ± 8.1
0.02 0.95 <0.001
10.1 ± 3.9 146.8 ± 35.6* 83.8 ± 27.9
9.3 ± 3.9 193.2 ± 151.7* 52.5 ± 31.8*
9.56 ± 6.2 281.9 ± 123.3 115.3 ± 45.9
0.93 0.06 0.003
interleukin 17, CD: cluster of differentiation.
e control.
t p< 0.05.
t p< 0.05.
p< 0.05.
< 0.05.
Figure 1 Dot plot for flow cytometric analysis of CD14++CD16+ (R2) and CD14+CD16+ (R3) monocytes for RA patients with early
or long standing disease according to the disease activity as well as in the control.
164 W.M. Radwan et al.remission compared with the healthy controls (p< 0.001,
p< 0.01 respectively). Comparisons according to the degree
of disease activity are presented in Table 2. A significant differ-
ence was present between patients with moderate and high dis-
ease activity, (p< 0.05). The CD14+CD16+ monocytepercentage was significantly lower only in RA patients with
remission compared with healthy controls (Table 2). However,
the CD16+ MFIR on CD14+ monocytes was significantly
higher in RA patients with high disease activity compared with
those having low and moderate activity (p< 0.05). The
Figure 2 CD14++CD16+ and CD14+CD16+ monocytes (percent and MFIR) and interleukin-17 among patients with early RA with
activity or remission as well as control.
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Figure 3 CD14++CD16+ and CD14+CD16+ monocytes (percent and MFIR) and interleukin-17 among patients with long standing
RA with activity or remission as well as control.
166 W.M. Radwan et al.percentage of CD14++CD16+ monocytes, CD16+ MFIR on
CD14++ monocytes and serum IL-17 according to the state of
disease activity is presented for early RA patients in Fig. 2 and
for long standing RA patients in Fig. 3. Significantly higher
levels of IL17 were found in RA patients with disease activitycompared to those with disease remission and healthy
controls (p< 0.01, p< 0.001 respectively) (Table 2). The level
was significantly higher in patients with high disease
activity than those with moderate disease activity (p< 0.01)
(Table 2).
Table 3 Association between the percentages and MFIR of CD14++CD16+ and CD14+CD16+ monocytes and IL17 levels with the
RF, anti-CCP and CRP positivity and response to DMARDs in RA patients.
Parameter
mean ± SD
Rheumatoid arthritis patients (n= 53)
CD14++CD16+ CD14+CD16+ IL17
% MFIR % MFIR
RF
+ve (45) 15.5 ± 5.9 105.7 ± 39.3 9.1 ± 4.9 212.7 ± 137.7 49.5 ± 41.4
ve (8) 13.8 ± 4.8 116.9 ± 33.2 8.5 ± 2.4 173.69 ± 140.4 40.1 ± 28.3
p 0.6 0.45 0.9 0.31 0.12
Anti-CCP
+ve (31) 14.8 ± 5.5 105.2 ± 34.4 8.2 ± 4.1 237.1 ± 154.9 61.4 ± 42.9
ve (22) 15.9 ± 6.2 110.5 ± 43.9 10.01 ± 5.2 164.1 ± 94.8 57.9 ± 40.3
p 0.65 0.86 0.3 0.02* 0.73
CRP
+ve (35) 15.6 ± 5.8 108.3 ± 36.6 9.3 ± 5.1 215.9 ± 138.1 67.1 ± 45.8
ve (18) 14.6 ± 5.9 105.6 ± 42.5 8.3 ± 3.4 189.1 ± 105.4 45.9 ± 27.4
p 0.6 0.86 0.83 0.55 0.1
DMARDs
Responders (48) 15.1 ± 5.8 107.3 ± 37.2 8.9 ± 4.5 207.2 ± 142.9 54.5 ± 36.3
Non-responders (5) 16.4 ± 6.1 108.7 ± 53.1 11.8 ± 5.5 202.9 ± 64.6 112.2 ± 55.6
p 0.65 0.93 0.14 0.58 0.017*
MFIR: mean fluorescent intensity ratio, CD: cluster of differentiation, RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide, CRP:
C-reactive protein. DMARDs: disease modifying antirheumatic drugs.
* Significantly different at p< 0.05.
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CD16+ MFIR on CD14++ monocytes did not significantly
associate with resistance to disease modifying antirheumatic
drugs (DMARDs), C-reactive protein (CRP), rheumatoid fac-
tor (RF) and anti-cyclic citrullinated peptide (anti-CCP) posi-
tivity (p> 0.05, Table 3). The percentage of CD14++CD16+
monocytes significantly correlated with IL17 levels (p< 0.002,
Table 4), but not with the disease duration, DAS28, number of
swollen and tender joints. CD16+ MFIR on CD14++ mono-
cytes did not significantly correlate with any of the previous
mentioned parameters. Both the percentage of CD14+CD16+
monocytes and CD16+ MFIR on CD14+ monocytes did not
significantly associate with DMARDs, CRP and RF positivity
(p> 0.05). CD16+ MFIR on CD14+ monocytes was signifi-
cantly higher in patients with positive anti-CCP (p= 0.023,
Table 3). Both the percentage of CD14+ CD16+ monocytes
and CD16+ MFIR on CD14+ monocytes did not correlate
with IL17, disease duration, DAS28, number of swollen and
tender joints (p> 0.05, Table 4). Significantly higher levelsTable 4 Correlation of the percentages and MFIR of CD14++CD
TJC, SJC, DAS28 and IL-17.
Parameters
r (p)
Disease duration TJC
CD14++CD16+
% 0.19 (0.2) 0.16 (0.34)
MFIR 0.08 (0.57) 0.22 (0.17)
CD14+CD16+
% 0.01 (0.95) 0.08 (0.63)
MFIR 0.14 (0.33) 0.22 (0.18)
MFIR: mean fluorescent intensity ratio, CD: cluster of differentiation, DA
swollen joint count, IL-17: interleukin-17.
* Significantly different at p< 0.05.of IL17 were found in RA patients resistant to DMARDs than
responding RA patients (p= 0.017) (Table 3).4. Discussion
Monocytes are crucial players in the perpetuation of immune
responses and joint damage in RA. Kawanaka et al. reported
higher frequency of CD16+ monocytes in the peripheral blood
of RA patients [23], but without distinguishing between sub-
populations of CD16+ monocytes. The CD14 low monocyte
subset has previously been the major focus of attention in
RA due to reports of increased numbers in inflammatory dis-
eases [23–26] and following reports suggested that they are the
main producers of TNF in controls [27]. However, in our cur-
rent study we found no significant difference in the percentage
of the CD14+CD16+ monocyte subset in RA patients
between early and long standing disease, or those in activity
and remission; and did not correlate with IL 17 levels, disease16+ and CD14+CD16+ monocytes with the disease duration,
SJC DAS28 IL17
0.31 (0.1) 0.19 (0.18) 0.37 (0.002)*
0.05 (0.8) 0.2 (0.16) 0.15 (0.22)
0.15 (0.43) 0.17 (0.23) 0.18 (0.16)
0.16 (0.39) 0.08 (0.6) 0.11 (0.38)
S28: disease activity score in 28 joints, TJC: tender joint count, SJC:
168 W.M. Radwan et al.duration and DAS28 score. CD14+CD16+ monocyte percent-
age was significantly lower in RA patients with disease remis-
sion compared with controls consistent with another study
[28]. CD16+ MFIR on CD14+ monocytes was significantly
higher in RA patients with high disease activity than in
patients with low and moderate RA disease activity.
Previous reports showed higher expression of CD16+ on
CD14++ monocyte subset in RA compared with controls
[23,29–32]. In this study, the percentage of CD14++CD16+
monocytes was significantly higher in long standing compared
with early RA patients and controls. Also it was higher in early
RA compared to controls. This was consistent with Rossol
et al. and Cooper et al., studies who revealed an expansion
of the intermediate CD14++CD16+ monocyte population in
patients with RA with no growth within the population of
nonclassical CD14+CD16+ monocytes [33,34]. Cooper et al.
reported significantly higher level of CD14++CD16+ mono-
cytes percentage in patients with long standing disease than
in early RA and controls while early RA patients were not sig-
nificantly different than controls. Klimek et al. found a signif-
icantly higher percentage of CD14++CD16+ monocytes in
patients with early RA compared to controls [35].
In the present study; the percentage of CD14++CD16+
monocytes was not significantly different between patients with
disease activity and remission or according to the degree of
activity which is consistent with Klimek et al. [35]. However,
a significant difference was present between patients with mod-
erate and high disease activity. CD16+ monocytes have been
demonstrated to be the main producers of TNF in response
to lipopolysaccharides [36]. It has demonstrated that mono-
cytes from RA patients show an enhanced capacity to produce
TNF in response to IgG-containing immune complexes and the
extent of TNF-production is correlated with the level of CD16
expression on CD14++ monocytes [33]. It has been demon-
strated that magnetic-bead isolated CD16+ monocytes adhere
to activated endothelium and migrate into the joint more effi-
ciently than CD16monocytes due to increased adhesion mole-
cule and chemokine receptor expression [37].
It has been shown that monocytes are important targets for
MTX treatment in RA patients [38,39]. In the present study, the
percentage of CD14++CD16+ monocytes did not significantly
associate with resistance to DMARDs. In contrast to our
findings, Cooper et al. demonstrated that increased CD16
expression on CD14++ monocytes in RA may be important
in determining non-response to MTX therapy [33]. Chara
et al. reported that the absolute number of circulating mono-
cytes, and the numbers of CD14++CD16, CD14++CD16+
and CD14+CD16+ subset cells, are strongly predictive of
the clinical response of naive RA patients to MTX treatment
[40].
IL-17 – producing CD4+ T cells have emerged as a major
pathogenic T cell population that is present at increased fre-
quencies in RA and correlates with disease severity [41]. The
underlying mechanisms of this expansion of the Th17 cell pop-
ulation are not fully understood, but in vivo–activated mono-
cytes from rheumatoid synovium have been shown to be able
to drive strong Th17 cell differentiation in vitro [8], indicating
a central role for direct T cell–monocyte contact in this
process. In this study, the percentage of CD14++CD16+
monocytes was significantly correlated with IL17 levels. Rossol
et al. reported that CD14++CD16+ monocytes were extre-
mely potent inducers of Th17 cell expansion. Their frequencyin the peripheral blood of RA patients correlated closely with
Th17 cell frequencies suggesting that the size of the CD14++
CD16+ subpopulation is indeed functionally linked to the
observed expansion of the Th17 cell population in RA [34].
In this study, IL17 levels were significantly higher in RA
patients than healthy controls, RA patients with disease activ-
ity than remission, patients with high activity than those with
moderate disease activity, RA patients resistant to DMARD
than responding patients which is consistent with previous
studies [32,42–44].
5. Conclusion
We have demonstrated that CD14++CD16+ monocyte sub-
population expanded in long standing than early RA patients
and was higher in those with high disease activity indicating its
potential pathogenic importance in driving the inflammatory
responses in RA. The positive correlation between CD14++
CD16+ monocyte percentage and serum level of IL17 indi-
cated that it may have a role in promotion and maintenance
of the pathogenetically relevant Th17 cell compartment in
RA. Further studies are needed to determine whether mono-
cyte CD16 expression levels could potentially be used as a
prognostic or predictive biomarker of response to methotrex-
ate therapy in RA. Furthermore, blockade of CD16 represents
an attractive target for future therapeutic intervention.Conflict of interest
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